Meeting
2022 ASCO Annual Meeting
A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors.
Authors
Dennis Brown
Edison Oncology Holding Corp., Menlo Park, CA
Dennis Brown , Jeffrey A. Bacha , James I. Geller , Patrick A. Thompson , Javier E. Oesterheld , Sarath Kanekal , Markos Leggas , Lorena Lopez , Neil Sankar , Noymi Yam , Lars M. Wagner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT04337177
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS10063)
DOI
10.1200/JCO.2022.40.16_suppl.TPS10063
Abstract #
TPS10063
Poster Bd #
274b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors.
First Author: Jeffrey A. Bacha
First Author: Stuart Cramer
Poster
2022 ASCO Annual Meeting
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.
First Author: Shakeel Modak
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster